Comparative effects of mibefradil and nifedipine gastrointestinal transport system on autonomic function in patients with mild to moderate essential hypertension

Journal of Hypertension

Volumn 19, Issue 2, 2001, Pages 279-285

  Pellizzer, Anne Marie ^a,b   Kamen, Peter W ^a,b   Esler, Murray D ^a,b   Lim, Stephen ^a,b   Krum, Henry ^a,b,c  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Autonomic nervous system; Calcium channel blockers; Essential hypertension; Heart rate variability; Norepinephrine

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; MIBEFRADIL; NIFEDIPINE; NORADRENALIN;

ADRENERGIC SYSTEM; ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; GASTROINTESTINAL TRACT; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; KINETICS; MALE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPATHETIC TONE;

EID: 0035142225     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200102000-00015     Document Type: Article

References (28)

1. The effect of diltiazem on mortality and reinfarction after myocardial infarction
2. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease
3. The risk of myocardial infarction associated with antihypertensive drug therapies
4. Pharmacological and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist
5. Pharmacologic and clinical perspectives on mibefradil: A new Tchannel selective calcium antagonist: Introduction
6. Evaluation of calcium-mediated vasoconstriction in chronic congestive heart failure
7. Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure
8. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure
9. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: Role of pharmacokinetics
10. Rate of increase in the plasma concentration of nifedipine as a major determinant of its haemodynamic effects in humans
11. 2+ channels by Ro 40-5967
12. Mibefradil (Ro 40-5967) is a selective blocker of myocardial T-type versus. L-type Ca channels
13. Non-invasive assessment of baroreflex sensitivity and relation to measures of heart rate variability in man
14. Measurement of total and organ-specific norepinephrine kinetics in humans
15. Cardiac and pulmonary norepinephrine release and removal in the dog
16. Further studies on renal nerve stimulation induced release of noradrenaline and dopamine from the canine kidney in situ
17. Release of noradrenaline into the cerebrovascular circulation in patients with primary hypertension
18. Dose-dependent suppression of norepinephrine appearance rate in plasma by clonidine in man
19. Poincare plot of heart rate variability allows quantitative display of parasympathetic nervous activity in humans
20. Effect of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients
21. New strategies in cardiovascular disease management: Summary of round table discussion
22. Pharmacology of the calcium antagonist mibefradil
23. Evidence for a sympatholytic effect of mibefradil in the pithed rat preparation
24. Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channel antgonist mibefradil (Ro 40-5967)
25. Effects of N-,P- and Q-type neuronal calcium channel antagonists on mammalian peripheral neurotransmission
26. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: The MACH-1 study